|
Gene: UMPS |
Gene summary for UMPS |
Gene summary. |
Gene information | Species | Human | Gene symbol | UMPS | Gene ID | 7372 |
Gene name | uridine monophosphate synthetase | |
Gene Alias | OPRT | |
Cytomap | 3q21.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A8K5J1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7372 | UMPS | CCI_3 | Human | Cervix | CC | 5.69e-06 | 5.19e-01 | 0.516 |
7372 | UMPS | LZE2T | Human | Esophagus | ESCC | 5.60e-06 | 5.95e-01 | 0.082 |
7372 | UMPS | LZE4T | Human | Esophagus | ESCC | 1.79e-07 | 2.54e-01 | 0.0811 |
7372 | UMPS | LZE7T | Human | Esophagus | ESCC | 3.31e-12 | 5.86e-01 | 0.0667 |
7372 | UMPS | LZE24T | Human | Esophagus | ESCC | 2.44e-08 | 2.30e-01 | 0.0596 |
7372 | UMPS | P1T-E | Human | Esophagus | ESCC | 1.28e-06 | 3.95e-01 | 0.0875 |
7372 | UMPS | P2T-E | Human | Esophagus | ESCC | 3.23e-15 | 4.56e-01 | 0.1177 |
7372 | UMPS | P4T-E | Human | Esophagus | ESCC | 1.21e-13 | 3.04e-01 | 0.1323 |
7372 | UMPS | P5T-E | Human | Esophagus | ESCC | 1.41e-23 | 5.70e-01 | 0.1327 |
7372 | UMPS | P8T-E | Human | Esophagus | ESCC | 2.22e-17 | 3.98e-01 | 0.0889 |
7372 | UMPS | P9T-E | Human | Esophagus | ESCC | 1.09e-21 | 4.78e-01 | 0.1131 |
7372 | UMPS | P10T-E | Human | Esophagus | ESCC | 6.34e-37 | 6.73e-01 | 0.116 |
7372 | UMPS | P11T-E | Human | Esophagus | ESCC | 2.35e-10 | 4.50e-01 | 0.1426 |
7372 | UMPS | P12T-E | Human | Esophagus | ESCC | 2.32e-21 | 3.96e-01 | 0.1122 |
7372 | UMPS | P15T-E | Human | Esophagus | ESCC | 1.41e-32 | 6.56e-01 | 0.1149 |
7372 | UMPS | P16T-E | Human | Esophagus | ESCC | 1.44e-31 | 6.14e-01 | 0.1153 |
7372 | UMPS | P17T-E | Human | Esophagus | ESCC | 5.60e-07 | 3.43e-01 | 0.1278 |
7372 | UMPS | P19T-E | Human | Esophagus | ESCC | 2.19e-04 | 4.72e-01 | 0.1662 |
7372 | UMPS | P20T-E | Human | Esophagus | ESCC | 3.39e-15 | 3.33e-01 | 0.1124 |
7372 | UMPS | P21T-E | Human | Esophagus | ESCC | 3.07e-21 | 4.58e-01 | 0.1617 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005087810 | Cervix | CC | regulation of body fluid levels | 78/2311 | 379/18723 | 3.20e-06 | 8.77e-05 | 78 |
GO:004873210 | Cervix | CC | gland development | 84/2311 | 436/18723 | 1.93e-05 | 3.54e-04 | 84 |
GO:00075654 | Cervix | CC | female pregnancy | 43/2311 | 193/18723 | 7.62e-05 | 1.04e-03 | 43 |
GO:00447064 | Cervix | CC | multi-multicellular organism process | 45/2311 | 220/18723 | 4.14e-04 | 4.21e-03 | 45 |
GO:00196939 | Cervix | CC | ribose phosphate metabolic process | 72/2311 | 396/18723 | 4.49e-04 | 4.48e-03 | 72 |
GO:00092599 | Cervix | CC | ribonucleotide metabolic process | 70/2311 | 385/18723 | 5.35e-04 | 5.18e-03 | 70 |
GO:00463908 | Cervix | CC | ribose phosphate biosynthetic process | 39/2311 | 190/18723 | 9.02e-04 | 7.77e-03 | 39 |
GO:00092608 | Cervix | CC | ribonucleotide biosynthetic process | 37/2311 | 182/18723 | 1.44e-03 | 1.13e-02 | 37 |
GO:00094109 | Cervix | CC | response to xenobiotic stimulus | 78/2311 | 462/18723 | 2.39e-03 | 1.70e-02 | 78 |
GO:00308797 | Cervix | CC | mammary gland development | 28/2311 | 137/18723 | 4.74e-03 | 2.83e-02 | 28 |
GO:000911710 | Cervix | CC | nucleotide metabolic process | 79/2311 | 489/18723 | 7.16e-03 | 3.85e-02 | 79 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
GO:0046390110 | Esophagus | ESCC | ribose phosphate biosynthetic process | 119/8552 | 190/18723 | 1.73e-06 | 2.06e-05 | 119 |
GO:000916516 | Esophagus | ESCC | nucleotide biosynthetic process | 150/8552 | 254/18723 | 1.12e-05 | 1.06e-04 | 150 |
GO:0009260110 | Esophagus | ESCC | ribonucleotide biosynthetic process | 112/8552 | 182/18723 | 1.12e-05 | 1.06e-04 | 112 |
GO:190129316 | Esophagus | ESCC | nucleoside phosphate biosynthetic process | 151/8552 | 256/18723 | 1.15e-05 | 1.08e-04 | 151 |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
hsa01240 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa00983 | Liver | Cirrhotic | Drug metabolism - other enzymes | 34/2530 | 80/8465 | 1.08e-02 | 3.57e-02 | 2.20e-02 | 34 |
hsa012401 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
hsa009831 | Liver | Cirrhotic | Drug metabolism - other enzymes | 34/2530 | 80/8465 | 1.08e-02 | 3.57e-02 | 2.20e-02 | 34 |
hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa009832 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa009833 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UMPS | SNV | Missense_Mutation | rs753854568 | c.722C>T | p.Ser241Leu | p.S241L | P11172 | protein_coding | tolerated(0.06) | benign(0.15) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
UMPS | SNV | Missense_Mutation | novel | c.360N>C | p.Leu120Phe | p.L120F | P11172 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
UMPS | SNV | Missense_Mutation | novel | c.1118N>A | p.Ser373Tyr | p.S373Y | P11172 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
UMPS | SNV | Missense_Mutation | c.1223N>A | p.Met408Lys | p.M408K | P11172 | protein_coding | tolerated(0.92) | benign(0) | TCGA-EY-A547-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
UMPS | SNV | Missense_Mutation | novel | c.880N>A | p.Val294Met | p.V294M | P11172 | protein_coding | deleterious(0.02) | possibly_damaging(0.571) | TCGA-PG-A917-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UMPS | SNV | Missense_Mutation | rs749083040 | c.86N>C | p.Lys29Thr | p.K29T | P11172 | protein_coding | deleterious(0) | benign(0.281) | TCGA-DD-A73A-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
UMPS | deletion | Nonsense_Mutation | novel | c.765_782delNNNNNNNNNNNNNNNNNN | p.Cys255_Ser261delinsTer | p.C255_S261delins* | P11172 | protein_coding | TCGA-ZP-A9CY-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
UMPS | SNV | Missense_Mutation | c.70G>T | p.Gly24Trp | p.G24W | P11172 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
UMPS | SNV | Missense_Mutation | c.843N>C | p.Lys281Asn | p.K281N | P11172 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-75-6214-01 | Lung | lung adenocarcinoma | Female | Unknown | III/IV | Unknown | Unknown | PD | |
UMPS | SNV | Missense_Mutation | novel | c.1222N>T | p.Met408Leu | p.M408L | P11172 | protein_coding | tolerated(0.33) | benign(0.003) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7372 | UMPS | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | capecitabine | CAPECITABINE | 20647221,28347776,16818689 | |
7372 | UMPS | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | fluorouracil | FLUOROURACIL | 20647221,16818689 | |
7372 | UMPS | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | 5-FLUORO-6-AMIDO-UMP | CHEMBL1164954 | 20452222 | |
7372 | UMPS | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | tegafur | TEGAFUR | 20647221,16818689 | |
7372 | UMPS | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | leucovorin | LEUCOVORIN | 20647221,16818689 |
Page: 1 |